New Dimension in Diagnosis.
Diagnosis is one of the most critical links in medicine today. Timely, accurate diagnosis can mean the difference between patient admission and discharge, between relief of symptoms and prolonged suffering, between early intervention and missed therapeutic opportunities and, in the gravest instances, between life and death.
Striving for sustained growth, we have adopted a strategy that encompasses the diagnostic continuum from protein validation to point-of-care diagnostics. Through combined expertise in diagnostic discovery and commercialization we are able to select large market opportunities, access potential markers of disease, identify proteins with high diagnostic utility, apply validated disease markers to advanced testing platforms, bring products to market, and educate physicians and other clinicians on new approaches to diagnosis, thereby benefiting patients. Underlying strengths that enable us to carry out this strategy include:
,Expertise in rapid, high-capacity antibody development, enabling high throughput screening of potential diagnostic markers and cost-efficient development of high affinity antibodies for use in commercialized products
,Extensive knowledge of analyte cloning and synthesis, signaling chemistry and microcapillary fluidics, which has contributed to the successful invention of proprietary testing platforms
,Track record for successfully moving novel diagnostics through the development pipeline and obtaining United States Food & Drug Administration (FDA) clearance or approval; and
,Extensive professional interaction and collaboration with customers, clinical researchers and the medical community.
,Better healthcare outcomes begin with better diagnosis. Better diagnosis begins with Biosite.